CD274 and obesity disorder: A multicenter study of NSCLC also found obesity to benefit the efficacy of anti-PD-1/PD-L1 antibodies, but only with the setting of ICI as second- or later-line therapy, with no such difference in the cohort with high PD-L1 expression (≥50%) and treated with ICIs as first-line therapy (48).